Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
April 21 2020 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will report first quarter 2020
financial results after market close on Wednesday, May 6, 2020.
Following the release of results, Douglas Bryant, president and
chief executive officer, and Randy Steward, chief financial
officer, will host an investment community conference call
beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to
discuss the results and answer questions. During the conference
call, the company will also discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
Investors may either join the live call by telephone, or join
via webcast:
- To participate in the live call by telephone from the U.S.,
dial 833-968-2118, or from outside the U.S., dial 778-560-2849, and
either request the “Quidel Q1 2020 Earnings Call” when prompted by
the conference call operator, or dial conference ID 627-6803.
- To join the live webcast, the call can be accessed through the
following link:
https://services.choruscall.com/links/qdel200506.html, or via the
Investor Relations section of the Quidel website
(http://ir.quidel.com).
The website replay will be available for 1 year. The telephone
replay will be available for 14 days beginning at 8:00 p.m. Eastern
Time (5:00 p.m. Pacific Time) on May 6th, 2020 by dialing
800-585-8367 from the U.S., or by dialing 416-621-4642 for
international callers, and entering pass code 627-6803.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's Triage® system of tests comprises a
comprehensive test menu that provides rapid, cost-effective
treatment decisions at the point-of-care (POC), offering a diverse
immunoassay menu in a variety of tests to provide diagnostic
answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I
and qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about
Quidel’s comprehensive product portfolio, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200421005754/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024